Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1470281 | 0.87 | ELANE (0.53) | ELANEALDH1A1RAB9ASMN1; SMN2SRD5A2 | |
| SCHEMBL1470251 | 0.86 | ELANE (0.47) | ELANEALDH1A1RAB9ASMN1; SMN2SRD5A2 | |
| SCHEMBL1471982 | 0.85 | ALDH1A1 (0.51) | ELANEALDH1A1RAB9ASMN1; SMN2SRD5A2 | |
| SCHEMBL1469834 | 0.84 | NAAA (0.48) | ELANEALDH1A1RAB9ASMN1; SMN2HTT | |
| SCHEMBL16606087 | 0.82 | MTNR1A (0.42) | ALDH1A1LMNA | |
| SCHEMBL14723237 | 0.80 | ELANE (0.58) | ELANEALDH1A1RAB9ASMN1; SMN2SRD5A2 | |
| SCHEMBL7716884 | 0.77 | SMN1; SMN2 (0.58) | ELANESMN1; SMN2SRD5A2 | |
| SCHEMBL29009109 | 0.77 | ELANE (0.59) | ELANEALDH1A1RAB9ASMN1; SMN2SRD5A2 | |
| SCHEMBL18978115 | 0.74 | KMT2A (0.69) | ELANEALDH1A1SRD5A2GAALMNA | |
| SCHEMBL1534312 | 0.74 | KMT2A (0.69) | ELANEALDH1A1SRD5A2GAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2130817-B1 | Polymerizable Type II photoinitiators and curable compositions | AGFA GRAPHICS NV (BE) | 2016-01-06 | — | — | EP | disclosed |
| CN-102056892-B | Multifunctional type II photoinitiators and curable compositions | AGFA GRAPHICS NV | 2015-07-22 | — | — | CN | disclosed |
| CN-102056890-B | Polymerizable type II photoinitiators and curable compositions | AGFA GRAPHICS NV | 2015-02-04 | — | — | CN | disclosed |
| US-8389769-B2 | Polymerizable type II photoinitiators and curable compositions | AGFA GRAPHICS NV (BE) | 2013-03-05 | — | — | US | disclosed |
| US-8362101-B2 | Multifunctional type II photoinitiators and curable compositions | AGFA GRAPHICS NV (BE) | 2013-01-29 | — | — | US | disclosed |
| CN-102056890-A | Polymerizable type II photoinitiators and curable compositions | AGFA GRAPHICS NV | 2011-05-11 | — | — | CN | disclosed |
| US-20110069130-A1 | MULTIFUNCTIONAL TYPE II PHOTOINITIATORS AND CURABLE COMPOSITIONS | AGFA GRAPHICS NV (BE) | 2011-03-24 | — | — | US | disclosed |
| US-20110063388-A1 | POLYMERIZABLE TYPE II PHOTOINITIATORS AND CURABLE COMPOSITIONS | AGFA GRAPHICS NV (BE) | 2011-03-17 | — | — | US | disclosed |
| WO-2009147054-A1 | MULTIFUNCTIONAL TYPE II PHOTOINITIATORS AND CURABLE COMPOSITIONS | AGFA GRAPHICS NV (BE) | 2009-12-10 | — | — | WO | disclosed |
| WO-2009147057-A1 | POLYMERIZABLE TYPE II PHOTOINITIATORS AND CURABLE COMPOSITIONS | AGFA GRAPHICS NV (BE) | 2009-12-10 | — | — | WO | disclosed |
| EP-2130818-A1 | Multifunctional Type II photoinitiators and curable compositions | AGFA Graphics NV (BE) | 2009-12-09 | — | — | EP | disclosed |
| EP-2130817-A1 | Polymerizable Type II photoinitiators and curable compositions | AGFA Graphics NV (BE) | 2009-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110069130-A1 | MULTIFUNCTIONAL TYPE II PHOTOINITIATORS AND CURABLE COMPOSITIONS | CRKL, CYTH2, CCNH | ELANE 4060/4885ALDH1A1 1579/4885RAB9A 2747/4885 |
| US-20110063388-A1 | POLYMERIZABLE TYPE II PHOTOINITIATORS AND CURABLE COMPOSITIONS | CCNH, CRKL, ERH | ELANE 4439/4885ALDH1A1 1584/4885RAB9A 2764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.